Business

VYNE Therapeutics to Participate in the H.C. Wainwright 3rd Annual Autoimmune & Inflammatory Disease Virtual Conference

BRIDGEWATER, N.J., March 20, 2025 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”), a clinical-stage biopharmaceutical company focused on developing differentiated therapies to treat chronic inflammatory and immune mediated conditions with high unmet need, today announced that VYNE’s management will participate in the H.C. Wainwright 3rd Annual Autoimmune & Inflammatory Disease Virtual Conference (Skin Diseases, Conditions and Disorders) being held on Thursday,

articleVyne Therapeutics Inc.March 20, 20251/company/vyne-therapeutics-inc/news/vyne-therapeutics-participate-h-c-120000813
VYNE Therapeutics to Participate in the H.C. Wainwright 3rd Annual Autoimmune & Inflammatory Disease Virtual Conference

About this update from Vyne Therapeutics Inc.

[{"type":"image","alt":"VYNE Therapeutics Inc.","displaySize":"","headline":null,"caption":"VYNE Therapeutics Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":70,"url":"https://media.zenfs.com/en/globenewswire.com/0dff937be94d3584ccbd9cdc44c8d95c"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/FTNQA7Twe5TgVrsG.wz_xA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTk4O2NmPXdlYnA-/https://media.zenfs.com/en/globenewswire.com/0dff937be94d3584ccbd9cdc44c8d95c","width":300,"height":70}},"lazy":false},{"type":"text","content":"BRIDGEWATER, N.J., March 20, 2025 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”), a clinical-stage biopharmaceutical company focused on developing differentiated therapies to treat chronic inflammatory and immune mediated conditions with high unmet need, today announced that VYNE’s management will participate in the H.C. Wainwright 3rd Annual Autoimmune & Inflammatory Disease Virtual Conference (Skin Diseases, Conditions and Disorders) being held on Thursday, March 27, 2025.","length":520,"tagName":"p"},{"type":"text","content":"Conference Presentation Details:","length":32,"tagName":"p"},{"type":"table","headerItems":[],"items":[{"val":[{"style":"max-width:25%;width:25%;min-width:25%;text-align:left;vertical-align:middle;vertical-align:top;","val":[{"type":"text","content":"Fireside Chat Timing:","length":21,"tagName":"p","attribs":{}}]},{"style":"max-width:75%;width:75%;min-width:75%;text-align:left;vertical-align:middle;vertical-align:top;","val":[{"type":"text","content":"Thursday, March 27, 2025, at 11:00 am ET","length":40,"tagName":"p","attribs":{}}]}]},{"val":[{"style":"text-align:left;vertical-align:middle;vertical-align:top;","val":[{"type":"text","content":"Registration:","length":13,"tagName":"p","attribs":{}}]},{"style":"text-align:left;vertical-align:middle;vertical-align:top;","val":[{"type":"text","content":"Webcast Link","length":12,"tagName":"p","attribs":{}}]}]},{"val":[{"colspan":"2","style":"text-align:left;vertical-align:middle;vertical-align:top;","val":[{"type":"text","content":" ","length":6,"tagName":"p","attribs":{}}]}]}],"length":86},{"type":"text","content":"A webcast replay will be available on the VYNE website for 90 days following the event.","length":87,"tagName":"p"},{"type":"text","content":"About VYNE Therapeutics Inc.VYNE i...

More updates from Vyne Therapeutics Inc.

VYNE Therapeutics Inc.biopharmaceutical companychronic inflammatoryVYNEVYNE Therapeutics Inc